Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells

KOSUKE NARITA1, TAKENORI FUJII2, TOSHIYUKI ISHIWATA2, TETSUSHI YAMAMOTO2, YOKO KAWAMOTO2, KIYOKO KAWAHARA2, NANDO NAKAZAWA2 and ZENYA NAITO2

1School of Medicine, 2Department of Pathology, Integrative Oncological Pathology, Nippon Medical School, Tokyo 113-8602, Japan

Received August 11, 2008; Accepted October 17, 2008

DOI: 10.3892/ijo_00000158

Abstract. Keratinocyte growth factor (KGF), which is also called fibroblast growth factor (FGF)-7, belongs to the FGF family. KGF is not commonly produced by human cancer cells, but the KGF receptor (KGFR) is expressed in most cancer cells and particularly highly expressed in well-differentiated types of cancer. Recently, it has been reported that vascular endothelial growth factor (VEGF)-A expression is induced by KGF in pancreatic cancer cells. VEGF-A is produced by some cancer cells and plays important roles in the angiogenesis and metastasis of cancer cells including those in the colorectum. In this study, we examined whether recombinant human KGF (rhKGF) induces major angiogenic growth factors including VEGF-A, FGF-2 and hepatocyte growth factor (HGF) in human colorectal cancer cells (HCT-15), which express a high level of KGFR, but a low or negligible level of KGF. rhKGF significantly increased the VEGF-A expression level in a serum-free medium of HCT-15 cells, but FGF-2 and HGF expression levels were too low to detect. Furthermore, the expression levels of the angiogenic growth factors were evaluated in KGF-transfected HCT-15 cells, which were induced to stably overexpress KGF by KGF gene transfection and mock-transfected cells (Mock). KGF and VEGF-A expression levels in the cells and the protein concentrations in serum-free medium were significantly higher in KGF-transfected HCT-15 cells than in Mock cells. In contrast, the FGF-2 and HGF mRNA expression levels were not significantly different between KGF-transfected HCT-15 cells and Mock cells and the protein concentrations in serum-free medium of the cells were below the detection level. These findings suggest that administration of rhKGF and over-expression of endogenous KGF genes in colorectal cancer cells increase VEGF-A production and may relate to angiogenesis in cancer.

Introduction

Keratinocyte growth factor (KGF), which is also known as fibroblast growth factor (FGF)-7, has been identified in a human embryonic lung fibroblast cell line (1,2). KGF is mainly produced by mesenchymal cells and affects epithelial cells that specifically express the KGF receptor (KGFR) (3). KGFR is tyrosine kinase FGF receptor-2 (FGFR-2) IIIb, which is a spliced variant of FGFR-2 (4). KGF was previously reported to modulate proliferation, differentiation, migration of cells and cell adhesion to extracellular matrices (5,6). KGF plays important roles in the wound healing of skin, proliferation of gut epithelial cells and angiogenesis in the rat cornea (7).

There are a few studies on human cancer cells producing KGF (8-11). In contrast, the expression of KGFR has been reported in various cancer cells (12). KGFR expression in cancer cells correlated to a well-differentiated histological type of esophageal cancer and early-type macroscopic findings, shallow wall invasion and expansive growth type of gastric cancer (8,13). Similarly, KGFR expression was associated with a well-differentiated histological type and shallow wall invasion in colorectal cancer (14). These findings suggest that KGFR expression in cancer cells does not directly correlate to the aggressiveness of cell growth. On the other hand, the coexpression of KGF and KGFR in endometrial, pancreatic, esophageal and colorectal cancer cells was reported (8-11).

Recently, our group has found that the coexpression of KGF and KGFR in cancer cells is significantly associated with VEGF-A expression and venous invasion of pancreatic cancer cells (10). Moreover, exogenous KGF enhances vascular endothelial growth factor (VEGF)-A expression and release in pancreatic cancer cell lines. These lines of evidence suggest that KGF is closely related to the expression of angiogenic growth factor and indirectly contributes to tumor growth.

Several types of growth factors contribute to tumor angiogenesis and VEGF-A, FGF-2/basic FGF and hepatocyte growth factor (HGF) are considered to be important angiogenic growth factors for the formation of microvessels adjacent to cancer cells (15). VEGF-A stimulates vascular endothelial cells, but not epithelial or stromal cells (16). In addition to vascular endothelial cells, FGF-2 stimulates the growth of
stromal fibroblasts and HGF stimulates the growth of epithelial cells (17-19). These growth factors are often expressed by tumor cells and they modulate the components and functions of the extracellular matrices close to cancer cells (20). These microvessels are considered to supply oxygen and nutrition to cancer cells and contribute to tumor growth (21,22). Furthermore, the microvessels are reported as one of the main pathways for distant metastases of cancer cells (23).

In this study, we examined whether KGF induces the expression of major angiogenic growth factors in colorectal cancer cells. We now report that KGF induces VEGF-A expression but does not affect FGF-2 and HGF expression in colorectal cancer cells.

Materials and methods

Materials. The following were purchased: an RNaseasy mini kit from Qagen GmbH (Hilden, Germany), a Transcriptor first-strand cDNA synthesis kit, LightCycler FastStart DNA Master SYBR-Green I and FuGENE 6 transfection reagent from Roche Diagnostics GmbH (Mannheim, Germany); Human VEGF, HGF, KGF/FGF-7 and FGF basic Quantikine colorimetric sandwich enzyme-linked immunosorbent assay (ELISA) kits, recombinant human KGF (rhKGF) and goat polyclonal anti-FGF-7 antibodies from Roche Diagnostics GmbH (Mannheim, Germany); Human VEGF, HGF, KGF/FGF-7 and FGF basic Quantikine colorimetric sandwich enzyme-linked immunosorbent assay (ELISA) kits, recombinant human KGF (rhKGF) and goat polyclonal anti-FGF-7 antibodies from R&D Systems Inc. (Westerville, OH, USA); rabbit polyclonal anti-VEGF-A antibodies (A-20) from Santa Cruz Biotech. (Santa Cruz, CA, USA); Texas Red-conjugated anti-rabbit IgG from Molecular Probes (Eugene, OR, USA); Texas Red-conjugated streptavidine and Vectashield mounting medium containing 4', 6-diamidino-2-phenylindole dihydrochloride (DAPI) from Vector Laboratories, Inc. (Burlingame, CA, USA); pIRE2EGFP from BD Bioscience Clontech (Palo Alto, CA, USA). All other chemicals and reagents were purchased from Sigma Chemical Corp. (St. Louis, MO, USA).

Colorectal cancer cell line. The human colorectal cancer cell line HCT-15 was obtained from the Institute for Aging and Cancer, Tohoku University (Sendai, Japan). The cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin at 37°C under a humidified 5% CO₂ atmosphere. The colorectal cancer cells expressed a high level of KGFR and a very low or a negligible level of KGF (24).

Effect of recombinant human KGF on angiogenic growth factor expression. Wild-type HCT-15 cells (1x10⁵/well), which were plated in six-well plates, were grown in 2 ml of RPMI-1640 medium with 10% FBS for 24 h and then cultured in serum-free medium for 48 h. Total RNA was extracted from the cancer cells using an RNeasy mini kit. cDNA was synthesized using a Transcriptor first-strand cDNA synthesis kit following the manufacturer's protocol. Quantitative real-time PCR (Q-PCR) analysis was performed using a LightCycler-FastStart DNA Master SYBR-Green I system. The real-time PCR primers used for KGF corresponded to nts 765-784 (5'-TTG-TGG-CAA-TCA-AAG-GGG-TG-3') and nts 905-927 (5'-CCT-CGG-TTG-TGT-GAT-TTA-GC-3') of human KGF cDNA (163 bp, NM_002009). The PCR primers used for VEGF-A corresponded to nts 1126-1148 (5'-GAG-GAG-GGC-AGA-ATC-ATC-AGG-A-3') and nts 1348-1369 (5'-TGG-TGA-GTT-TTG-ATG-CGC-ATA-A-3') of human VEGF-A cDNA (244 bp, NM_003376). The PCR primers used for FGF-2 corresponded to nts 629-653 (5'-GAG-GAG-CCA-CCC-TCA-CAT-GCT-A-3') and nts 835-858 (5'-CAG-TTC-GTT-TCA-GTG-CCA-CAT-ACC-3') of human FGF-2 cDNA (230 bp, NM_002006). The PCR primers used for HGF corresponded to nts 250-272 (5'-GCA-GAG-OGA-CAA-AGG-AAA-AGA-3') and nts 452-473 (5'-CTA-TTG-AGG-GGG-ACG-CAG-CCG-3') of human HGF cDNA (224 bp, NM_000601). The PCR primers used for 18S ribosomal RNA (RS-18) corresponded to nts 184-207 (5'-AAA-GCA-GAC-ATT-GAC-CTC-ACC-AAG-3') and nts 319-341 (5'-GAG-ACC-TGG-CTG-TAT-CTT-CCA-TC-3') of human RS-18 cDNA (158 bp, NM_002351). A PCR reaction mixture containing 2 μl of template cDNA, 3 mM MgCl₂, 0.5 μM primers and 2 μl of LightCycler-FastStart DNA Master SYBR-Green I mix was prepared in a capillary tube. Q-PCR was carried out in a LightCycler and the PCR products were analyzed using LightCycler data analysis software Ver. 3.5 (Roche). The optimized program involved denaturation at 95°C for 10 min, followed by 50 cycles of amplification: at 95°C for 10 sec, at 60°C for 10 sec and at 72°C for 10 sec for VEGF-A; at 95°C for 10 sec, at 60°C for 10 sec and at 72°C for 8 sec for KGF; at 95°C for 10 sec, at 63°C for 10 sec and at 72°C for 10 sec for FGF-2; at 95°C for 10 sec, at 60°C for 10 sec and at 72°C for 10 sec for HGF; and at 95°C for 10 sec, at 64°C for 10 sec and at 72°C for 7 sec for RS-18. To confirm amplification specificity, PCR products were subjected to melting curve analysis. Results were expressed as target/RS-18, as an internal standard concentration ratio. Gene expression measurement was performed in triplicate.
Immunofluorescence analyses of KGF and VEGF-A in KGF-transfected HCT-15 cells. KGF-transfected HCT-15 cells and Mock cells (1x10^5/well) plated in six-well plates were grown in 2 ml of RPMI-1640 medium with 10% FBS for 24 h and then cultured in serum-free medium for 48 h. The cells were incubated with anti-KGF (1:50) or VEGF-A antibodies (1:50) in PBS containing 1% bovine serum albumin (BSA) for 16 h at 4˚C. As a negative control, HCT-15 cells were incubated with PBS containing 1% BSA. For VEGF-A staining, the cells were washed with PBS and then incubated with Texas Red-conjugated anti-rabbit IgG for 1 h. For KGF staining, the cells were incubated with biotinylated polyclonal rabbit anti-goat IgG for 1 h and then immersed in Texas Red-conjugated streptavidine. The cells were washed with PBS and then mounted with Vectashield mounting medium containing DAPI. Fluorescent images were acquired using a confocal laser scanning microscope Digital Eclipse TE 2000-E (Nikon Insteck Co., Ltd., Tokyo, Japan) and a x100 immersion lens (Nikon Palm Apo VC) with blue diode (BD) and argon (Ar) lasers. The images were analyzed using confocal microscope Digital Eclipse C1 control software EZ-C1 (version 2.30) (Nikon Insteck). The excitation wavelength for Texas Red was 543 nm and emission was detected and recorded using a 605- to 675-nm band-pass filter. In addition, the excitation wavelength for DAPI was 405 nm and emission was detected and recorded using a 432- to 446-nm band-pass filter.

ELISA of angiogenic growth factors in culture supernatant of KGF-transfected HCT-15 cells. KGF-transfected HCT-15 cells and Mock cells (1x10^5/well) plated in six-well plates were grown in 2 ml of RPMI-1640 medium with 10% FBS for 24 h and then cultured in serum-free medium for 48 h. The culture supernatants were collected and their KGF, VEGF-A, FGF-2, and HGF concentration were measured using ELISA kits. This study was performed in two separate experiments, each conducted in triplicate.

Statistical analysis. All values were expressed as mean ± SE. To analyze the effect of rhKGF on HCT-15 cells, Welch's t-test was performed. Mann-Whitney's U test was performed to compare the expression levels of angiogenic growth factors in both groups. P<0.05 was considered significant in all analyses. Computation was performed using the StatView J version 5.0 (SAS Institute, Inc., Cary, NC, USA) software package.

Results

Effect of rhKGF on concentrations of angiogenic growth factors in culture supernatant of HCT-15 cells. To examine the effect of exogenous KGF on the induction of angiogenic growth factors in colorectal cancer cells, rhKGF was administered to HCT-15 cells. HCT-15 cells were used to examine the paracrine effect of KGF on colorectal cancer cells, because the cells express a very low or a negligible level of KGF and a high level of KGFR (24). The VEGF-A level in the serum-free medium was significantly higher for rhKGF-administered HCT-15 cells than for the untreated control (Fig. 1, P<0.05). However, the FGF-2 and HGF expression levels were too low to detect in the untreated control and rhKGF-administered HCT-15 cells (data not shown).

KGF, VEGF-A, FGF-2 and HGF mRNA expression levels in KGF-transfected HCT-15 cells. Next, we attempted to clarify the effect of endogenously produced KGF on angiogenic growth factor expression in HCT-15 cells. The protein concentrations of KGF in a culture supernatant of KGF-transfected HCT-15 cells, Mock and wild-type HCT-15 cells were examined by ELISA (Fig. 2). Two clones of KGF-transfected HCT-15 cells (KGF-D and KGF-E), which express a high level of KGF mRNA and Mock cells were used for the following experiments. We examined the expression levels of angiogenic growth factors in Mock, KGF-D and KGF-E cells.
The expression levels of KGF, VEGF-A, FGF-2 and HGF mRNAs in KGF-D, KGF-E and Mock cells were determined by Q-PCR analysis. KGF-D and KGF-E cells expressed significantly higher levels of KGF and VEGF-A mRNAs than HCT-15-mock cells (Mock) (A and B, respectively, p<0.01). In contrast, there were no statistical differences in FGF-2 mRNA level between the two groups (C).

Immunofluorescence analysis of KGF and VEGF-A localization in KGF-transfected HCT-15 cells. To confirm the increased expression levels of KGF and VEGF-A proteins in the cytoplasm of KGF-transfected HCT-15 cells, immunofluorescence analysis was performed. KGF signals were stronger at the periphery of the cytoplasm of KGF-E cells than at that of Mock cells (Fig. 4A and B, respectively). VEGF-A signals were diffuse and stronger in the cytoplasm of KGF-E cells than in that of Mock cells (Fig. 4C and D, respectively). Negative controls without primary antibodies did not show any positive signals (B and D, insets).

Concentrations of angiogenic growth factors in the culture supernatant of KGF-transfected HCT-15 cells. To estimate whether the angiogenic growth factors were effectively secreted into the extracellular space, ELISA of the VEGF-A, FGF-2 and HGF proteins in the culture supernatant was performed. Compared with the Mock cells, the culture supernatant of KGF-transfected HCT-15 cells (KGF-D and KGF-E) contained significantly higher concentrations of VEGF-A (p<0.05, Fig. 5). FGF-2 and HGF protein concentrations were too low to detect by sandwich ELISA in both groups (data not shown).
Discussion

Several studies showing exogenous KGF involvement in tumorigenesis have been reported. Exogenous KGF stimulated the growth of 5 of 35 human solid tumor cell lines, which were two lung, one stomach, one breast and one colorectal cancer cell lines. In five colorectal cancer cell lines, rhKGF stimulated the growth of only one cancer cell line, namely, LOVO (25). KGF stimulates motility of estrogen receptor (ER)-positive breast cancer cells and gastric cancer cells (26,27). We have recently reported that KGF increases the adhesion activity of the ER and progesterone receptor (PR)-positive well-differentiated endometrial cancer cells to fibronectin and does not stimulate cell growth (9). These findings suggest that the KGF-KGFR system modulates cell growth and other biological functions.

Recently, we have found that exogenous KGF increases the expression and secretion levels of VEGF-A in pancreatic cancer cells (10). VEGF-A, which is induced by exogenous KGF, may stimulate the growth of pancreatic cancers through tumor angiogenesis. In colorectal cancer, we found in this study, that rhKGF induced VEGF-A expression. KGF is reported to activate nuclear factor κB (NF-κB), which in turn induces the expression of VEGF-A, MMP-9 and urokinase-type plasminogen activators and also stimulates migration and invasion of human pancreatic ductal epithelial cells (28). A similar intracellular pathway may exist in colorectal cancer cells. To the best of our knowledge, this is the first study showing that KGF induces VEGF-A in colorectal cancer. Our group previously reported that KGFR is expressed in 62.5% of colorectal cancer patients and KGF is highly expressed in enterochromaffin cells and fibroblasts located close to cancer cells (11). These findings may indicate that KGF, synthesized by other cell types or exogenously administered, plays significant roles in colorectal cancer cell growth and/or distant metastasis through the formation of neovasculature adjacent to cancer cells.

A human KGF product named palifermin has already been introduced in medical treatment. Palifermin is produced by recombinant DNA technology in Escherichia coli and it differs from endogenous human KGF in that the first 23 N-terminal amino acids have been deleted to improve protein stability. Palifermin is clinically used to treat gingivostomatitis and oral ulcers that are caused by chemotherapy and/or radiation for bone marrow transplantation to leukemia patients (29). In a randomized phase II clinical trial in advanced colorectal cancer patients treated with 5-FU and leucovorin, the patients who received palifermin had a lower incidence of ulcerative oral mucositis and their prognosis was nearly the same as that of the control group (30). However, palifermin has not been fully tested for all types of cancer (12). Our findings suggest that further studies may be necessary to determine whether palifermin can be safely used in KGFR-expressing types of malignant tumor cells such as colorectal cancer. In contrast to VEGF-A, exogenous KGF did not stimulate the expression and secretion of FGF-2 and HGF in colorectal cancer cells. FGF-2 and HGF are also important angiogenic factors in some types of cancer cells and they have putative NF-κB binding sites in the promoter region. The reason KGF induced VEGF-A, but not FGF-2 or HGF is unclear. Each promoter activity may cause different expression patterns of the angiogenic growth factors. Further studies are required to clarify the effects of KGF on tumor angiogenesis in vivo.

We have previously examined the biological role of KGF in HCT-15 cells (24). HCT-15 cells express a high level of KGFR, but a very low or a negligible level of KGF. The growth rate is not altered in stably KGF-transfected HCT-15 cells, but the activity of adhesion to type IV collagen through ERK and FAK signaling pathways increases in the cells in vitro. In this study, KGF-transfected HCT-15 cells produced significantly larger amounts of KGF and VEGF-A than Mock cells. This study may indicate that the over-expression of KGF genes in tumor cells increases VEGF-A production and the KGF-KGFR autocrine loop contributes to VEGF production in cancer cells. We have recently reported that coexpression of KGF and KGFR in pancreatic cancer cells strongly correlates with VEGF-A expression and venous invasion of cancer cells (10). KGF short hairpin (sh) RNA-transfected pancreatic cancer cells express a lower level of KGF and attenuate VEGF-A expression and release in culture medium. Coexpression of KGF and KGFR was previously reported in colorectal cancer cells and anti-VEGF therapy is now used for patients who suffer from various cancers including colorectal cancer. The anti-VEGF therapy may be a more effective treatment for KGF/KGFR co-expressing colorectal cancer patients. Further study is required to clarify the correlation of KGF and KGFR coexpression with VEGF-A expression in colorectal cancer patients.

In summary, exogenous and endogenous KGF induced the expression of VEGF-A, but not FGF-2 and HGF in colorectal cancer cells. VEGF-A induced by KGF may contribute to the aggressiveness of colorectal cancer through tumor angiogenesis.

Acknowledgements

The authors appreciate Mr. Kiyoshi Teduka, Ms. Taeko Suzuki and Dr Norio Motoda (Integrative Oncological Pathology, Nippon Medical School) for excellent technical assistance. We also thank Dr Mitsuhiro Kudo (Integrative Oncological Pathology, Nippon Medical School) and Dr Shunji Ishiwata (Department of Pharmaceutics, Kinki University) for invaluable advice. This study was supported in part by a Grant-in-Aid for Scientific Research (C, No. 19591603 for Z.N.) from the Japan Society for the Promotion of Science and by a Grant-in-Aid for Young Scientists from the Japan Society for the Promotion of Science to Tetsushi Yamamoto (B, No. 20790974).

References